Signaling pathways underlying changes in the contractility of the stomach fundus smooth muscle in diabetic rats

Dysfunction of gastrointestinal (GI) motility is a common complication in patients with diabetes mellitus (DM). Studies related to changes in fundus contraction induced by inhibitors in DM are not well known. Therefore, this study aimed to investigate the signaling pathways involved in the changes i...

Full description

Saved in:
Bibliographic Details
Published in:Archives of pharmacal research 2020, 43(6), , pp.666-675
Main Authors: Kim, Dong Min, Khing, Tin Myo, Thein, Wynn, Choi, Won Seok, Shin, Chang Yell, Sohn, Uy Dong
Format: Article
Language:English
Subjects:
Animals
Cell Membrane - metabolism
Diabetes Mellitus, Experimental - chemically induced
Diabetes Mellitus, Experimental - metabolism
Gastric Fundus - metabolism
Male
Medicine
Muscle Contraction
Muscle, Smooth - metabolism
Pharmacology/Toxicology
Pharmacy
Rats
Rats, Sprague-Dawley
Research Article
Signal Transduction
Streptozocin - administration & dosage
약학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dysfunction of gastrointestinal (GI) motility is a common complication in patients with diabetes mellitus (DM). Studies related to changes in fundus contraction induced by inhibitors in DM are not well known. Therefore, this study aimed to investigate the signaling pathways involved in the changes in the contraction of fundus smooth muscle obtained from control and DM rats. DM was induced by injecting streptozotocin (65 mg/kg) into Sprague–Dawley rats. The rats were sacrificed after 14 days. Fundus smooth muscle contraction was stimulated using electrical field stimulation (amplitude, 50 V; duration, 1 min; frequency, 2–20 Hz) and acetylcholine (0.1 mM). The inhibitor-mediated cell membrane was pre-treated with atropine, verapamil, methysergide, ketanserin, ondansetron, and GR 113808. Inhibitors related to intracellular signaling, such as U73122, chelerythrine, l -NNA, were also used. ML-9 and Y-27632 were identified as inhibitors of factors of myosin light chain (MLC). The contractility was observed to be lower in the DM group than in the control group. Further, the activities of phospholipase C (PLC), protein kinase C (PKC), and myosin light chain kinase (MLCK) were decreased in the DM group. DM reduced the activity of PLC, PKC, and MLCK, which resulted in a decrease in the contractility of the fundus smooth muscle. Therefore, our results present the mechanism of this DM-mediated GI disorder.
ISSN:0253-6269
1976-3786
DOI:10.1007/s12272-020-01244-z